Navigation Links
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
Date:8/5/2010

allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue. AEZS-108 has already been studied in gynecologic cancers and has been shown to be effective and well tolerated in endometrial and ovarian cancer. Preclinical studies in animal models with prostate cancer also have demonstrated positive results with the drug.

AEZS-108 is currently in a Phase 2 trial conducted in Europe by the German AGO Study Group (Study AGO-GYN5), in advanced ovarian and endometrial cancer. Positive final Phase 2 results for ovarian cancer were disclosed in June 2010 at the annual American Society of Clinical Oncology ("ASCO") meeting, while those for endometrial cancer are expected by year-end. AEZS-108 has been granted orphan-drug designation by the FDA and has received a positive opinion for Orphan Medicinal Product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of ovarian cancer.

About Prostate Cancer

According to the National Cancer Institute (NCI), prostate cancer is the second most prevalent type of cancer after lung cancer. The NCI estimates that 217,730 men will be diagnosed with and 32,050 men will die of prostate cancer in 2010 in the United States alone.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 /PRNewswire/ ... research report is available in its catalogue: ... 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials are materials that are readily decomposed ... differs from conventional non-degradable packaging in terms ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Chelating Agents Market ... About Chelating Agent A chelating agent is ... with metal ions, thereby forming a metal-ion complex. ... have on chemical processes, formulations, and the environment ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7DTU researchers film protein quake for the first time 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... ... ... ... ...
... ... Evonik for Industrial Biotechnology R&D Processes , ... Basel, Switzerland (PRWEB) February 23, 2010 -- ... announced an extended partnership with Evonik, a leading life science, specialty chemicals and ...
... Medicine , Susan Huang and colleagues describe the use ... by integrating two freely available software packages, to identify ... data from patients admitted to a 750-bed academic medical ... authors found that the tool identified a number of ...
Cached Biology Technology:Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 2Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 3Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 4Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 5Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 6Evonik Extends Long-term Research & Development Partnership with Genedata 2Evonik Extends Long-term Research & Development Partnership with Genedata 3Evonik Extends Long-term Research & Development Partnership with Genedata 4Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 2Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 3Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 4
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
(Date:8/28/2014)... the most commonly diagnosed learning disability in the ... occurs when the regions of the brain that ... use of non-invasive functional neuroimaging tools has helped ... However, most prior work has focused on only ... gap in our understanding of how multiple brain ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2Dyslexic readers have disrupted network connections in the brain 2
... OTTAWA November 14, 2010 One of the largest, ... University of Ottawa Heart Institute (UOHI), conclusively proves that a ... while reducing risk of death by 24% compared to the ... and Dr. George Wells at the Heart Institute, brings the ...
... Kritzer, assistant professor in the School of Arts and ... awarded one of 33 NIH Director,s New Innovator Awards, ... National Institutes of Health. The NIH Director,s New ... creative new investigators with highly innovative research ideas at ...
... the association for informatics professionals, honors four leaders ... 2010, with the annual presentation of its Signature ... Monday, Nov. 15 at the Opening Session of ... Informatics in Washington, D.C., before an audience of ...
Cached Biology News:Synchronizing a failing heart 2Tufts University chemist earns prestigious award for promising research on drug development 2Recognition given for ground-breaking advancements in digitalizing health data and information 2Recognition given for ground-breaking advancements in digitalizing health data and information 3Recognition given for ground-breaking advancements in digitalizing health data and information 4
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... Since the Flp-In System creates ... produce equivalent levels of the protein ... demonstrated in Figure 3 (click link ... sequence for chloramphenicol-acetyl transferase (CAT) was ...
... Multiple solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, p-xylene, dimethyl sulfoxide, ... * Range: 12-position switchable: ... ... ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
Biology Products: